BYSI - NASDAQ

BeyondSpring Inc.

BYSI·NASDAQ

$1.77

+8.6%

HealthcareBiotechnology

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$72.78M

EPS-0.2000

P/E Ratio-8.85

Earnings Date08/12/2026

25.93M

Assets

-24%

3Y-44.0%

5Y-78.0%

10Y+74.0%

49.92M

Total Liabilities

3Y+1.0%

5Y+98.0%

10Y+1813.0%

-23.99M

Total Equity

68%

3Y+698.0%

5Y-126.0%

10Y-295.0%

BeyondSpring Inc. Funding & Solvency Profile

BYSI · NASDAQ

Current Assets

Cash & Cash Equivalents7.79M

Net Receivables0.00

Inventory0.00

Other Current Assets8.32M

Total Current Assets21 M

Non-Current Assets

Property, Plant & Equipment471.00K

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets4.58M

Total Non-Current Assets5 M

Total Assets

25.93M

Financial Health Analysis

Current Ratio

1.54x

Strong liquidity. The company has adequate resources to meet short-term liabilities.

Working Capital

7 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

81% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

BeyondSpring Inc. Balance Sheet

BYSI • NASDAQ

BeyondSpring Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	7.8M	2.9M	15.3M	34.4M	41.6M	109.5M	35.9M	3.9M	27.5M	11.7M	10.8M	392K
Short-Term Investments	4.8M	0.0	0.0	2.9M	30.7M	0.0	0.0	0.0	3.1M	0.0	0.0	0.0
Cash & Short-Term Investments	12.6M	2.9M	15.3M	37.3M	72.4M	109.5M	35.9M	3.9M	30.6M	11.7M	10.8M	392K
Net Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	764K
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	764K
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2M	0.0	799K	89K	16K
Prepaids	0.0	240K	292K	492K	1.7M	3.5M	4.5M	292K	1.5M	360K	89K	16K
Other Current Assets	8.3M	25.4M	2.8M	763K	1M	358K	410K	1.7M	264K	2.7M	26K	2K
Total Current Assets	20.9M	28.6M	18.4M	38.5M	75.1M	113.4M	40.9M	5.9M	32.3M	14.7M	10.9M	1.2M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	471K	752K	1M	7.4M	5M	2.4M	2.7M	282K	123K	80K	34K	0.0
Other Non-Current Assets	4.6M	5M	5.3M	347K	1.6M	1.3M	946K	910K	361K	121K	0.0	0.0
Total Non-Current Assets	5.1M	5.7M	6.4M	7.7M	6.5M	3.6M	3.7M	1.2M	484K	201K	34K	0.0
Total Assets	25.9M	34.3M	24.8M	46.2M	81.6M	117M	44.6M	7.1M	32.8M	14.9M	11M	1.2M
LIABILITIES
CURRENT LIABILITIES
Total Payables	363K	296K	579K	1.1M	1.7M	3.1M	2.5M	9.6M	3.4M	444K	300K	206K
Accounts Payable	363K	295K	561K	1.1M	1.7M	2.2M	2.5M	9.6M	3.4M	444K	300K	206K
Other Payables	0.0	1K	18K	32K	0.0	857K	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	612K	967K	2.5M	3.9M	5.6M	6.1M	5.5M	807K	1.4M	210K	0.0
Short Term Debt	320K	0.0	258K	0.0	1.6M	0.0	29K	0.0	0.0	210K	0.0	0.0
Capital Lease Obligations (Current)	0.0	282K	0.0	966K	538K	787K	537K	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	1K	16K	32K	4M	857K	798K	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	28.6M	27.4M	1.8M	1.4M	1.4M	1.4M	6.9M	0.0	0.0	1.4M	0.0	0.0
Other Current Liabilities	-15.7M	-17.6M	4.4M	1.5M	6.2M	2.9M	-6M	1.4M	606K	523K	802K	2.5M
Total Current Liabilities	13.6M	11M	8M	7.4M	15.2M	13.8M	10.1M	16.4M	4.8M	2.6M	1.3M	2.7M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	2.2M	1.4M	0.0	0.0	0.0	0.0	7.8M
Deferred Revenue (Non-Current)	28.6M	27.4M	28.2M	34.2M	37.9M	7.9M	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	5.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	7.7M	9.9M	11.6M	3.7M	709K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	36.3M	37.6M	40.3M	41.9M	45.6M	11.5M	3.4M	9.6M	3.4M	654K	300K	7.8M
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.6M	-3.4M	-654K	-300K	0.0
Capital Lease Obligations	0.0	589K	589K	5M	2M	2.1M	2.5M	0.0	0.0	0.0	0.0	0.0
Total Liabilities	49.9M	48.6M	48.3M	49.2M	60.7M	25.2M	13.4M	16.4M	4.8M	2.6M	1.3M	10.6M
SHAREHOLDERS' EQUITY
Common Stock	4K	4K	4K	4K	4K	4K	3K	2K	2K	2K	2K	1K
Additional Paid-In Capital	375.7M	373.2M	368.6M	368.9M	369.2M	366.5M	247M	171M	151.1M	44.4M	29.1M	2.8M
Retained Earnings	-408.4M	-407.4M	-396.3M	-375.3M	-342M	-277.8M	-216.8M	-178.8M	-123.9M	-32.1M	-20.1M	-12.1M
Accumulated Other Comprehensive Income/Loss	602K	1.3M	894K	436K	-523K	-297K	140K	42K	-182K	-91K	-53K	-42K
Total Stockholders' Equity	-32.2M	-32.9M	-26.8M	-6M	26.7M	88.3M	30.3M	-7.8M	27.1M	12.2M	9M	-9.4M
Total Equity	-24M	-14.3M	-23.5M	-3M	20.9M	91.8M	31.1M	-9.4M	28M	12.3M	9.7M	-9.4M
Minority Interest	8.2M	18.6M	3.3M	3M	-5.8M	3.5M	854K	-1.6M	960K	147K	708K	0.0
SUMMARY
Total Liabilities & Equity	25.9M	34.3M	24.8M	46.2M	81.6M	117M	44.6M	7.1M	32.8M	14.9M	11M	1.2M
Total Investments	4.8M	0.0	0.0	2.9M	30.7M	0.0	0.0	0.0	3.1M	0.0	0.0	0.0
Total Debt	320K	589K	847K	5M	3.6M	4.3M	3.9M	0.0	0.0	210K	0.0	7.8M
Net Debt	-7.5M	-2.3M	-14.5M	-29.4M	-38.1M	-105.2M	-32M	-3.9M	-27.5M	-11.5M	-10.8M	7.4M
Shares Outstanding	40,332,320	40,332,320	40,332,320	40,332,320	40,332,320	40,332,320	40,332,320	40,332,320	40,332,320	40,332,320	40,332,320	40,332,320

SEC Filings

BYSI - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 13, 2026	May 13, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 25, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 25, 2026	March 25, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 15, 2025	December 15, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 21, 2025	November 17, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 12, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 12, 2025	November 12, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 23, 2025	September 22, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 16, 2025	September 15, 2025	2025	View Filing

Showing 1 to 10 of 107 filings

Related Guides

Blog Categories

Continue your BYSI research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.